Aamir Abbas, DO
Pain Medicine · Dover, NHNPI 1861818957
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Abbott at 32.2% of the total. Reporting peaked in 2024 at $1,432 and has fallen 81.6% since, to $263 in 2025. That places this record below the midpoint for pain medicine clinicians in NH, where the typical reported total is $1,993.
Across 25 payments — averaging $73.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$593
- Boston Scientific$541
- SPR Therapeutics, Inc$471
- Vertos Medical, Inc.$139
- Nevro Corp.$27
- Alnylam Pharmaceuticals Inc.$26
- plus $47 from 2 others
What the payments were for
- Travel & lodging$73840%
- Food & beverage$1,10660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $593 |
| Boston Scientific | 14 | $541 |
| SPR Therapeutics, Inc | 3 | $471 |
| Vertos Medical, Inc. | 1 | $139 |
| Nevro Corp. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Saluda Medical Americas, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRINT PNS System$454
- CARDIOMEMS$424
- ETERNA$160
- mild Device Kit$139
- GENERAL PAIN MANAGEMENT$127
How this compares
$1,844 in reported general payments places this provider in the 45th percentile of 38 pain medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 25 | $1,615 |
| Gabapentin | 73 | $807 |
| Pregabalin | 21 | $405 |
| Cyclobenzaprine Hcl | 12 | $317 |
| Tizanidine Hcl | 28 | $198 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Dover
- Dennis ThapaDover$13K
- Thomas ZoukiDover$9K
- Jung KimDover$4K
- Tennison MalcolmDover$3K
- Praveen SuchdevNashua$72K
- Zubin BatlivalaBedford$18K
- Bert FichmanLebanon$15K
- Michael BovaLebanon$12K
- James MirazitaNashua$10K
- Robert LehnPortsmouth$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.